We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Anti-Anthrax Drug Gets AIDAC Recommendation on Resubmission
Anti-Anthrax Drug Gets AIDAC Recommendation on Resubmission
November 9, 2012
The FDA’s Anti-Infective Drugs Advisory Committee on Nov. 2 recommended approval of GlaxoSmithKline’s (GSK) 40-mg/kg raxibacumab IV solution, with or without an antimicrobial, to treat adults infected in an airborne anthrax attack.